Tarsus Pharmaceuticals, Inc.
TARS
Rank in Stocks
#4598
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Share Price
$71.12
Last synced: 2026-10-20
Market Cap
$3.33B
Change (1 day)
2.33%
Change (1 year)
0.42%
Country
US
Trade Tarsus Pharmaceuticals, Inc. (TARS)
Category
Healthcare
Revenue for Tarsus Pharmaceuticals, Inc. (TARS)
Revenue in Jun 2026 TTM: $606.33M
According to Tarsus Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is $606.33M. In 2023 the company made a revenue of $17.45M a decrease compared to the revenue in the year 2022 that was $25.82M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Tarsus Pharmaceuticals, Inc. from 2018 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $606.33M | 231.41% |
| 2024 | $182.95M | 948.62% |
| 2023 | $17.45M | -32.42% |
| 2022 | $25.82M | -54.73% |
| 2021 | $57.03M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 1,982.08% |
US
|
|
| $2.23B | 267.46% |
US
|
|
| $15.74B | 2,496.66% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 893.07% |
NL
|
